ArticleVaccines2025

A Phase 3 Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Vaccine, Compared with PPSV23, in Adults ≥50 Years of Age (STRIDE-10).

Veronika Jotterand et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.